Pulse Biosciences Grants Equity Incentive Awards to New Employees
September 19 2018 - 4:05PM
Business Wire
Pulse Biosciences, Inc. (NASDAQ: PLSE), a medical technology
company developing a proprietary therapeutic tissue treatment based
on its Nano-Pulse StimulationTM (NPSTM) platform, announced today
that the Compensation Committee of the company’s Board of Directors
granted non-qualified stock options covering an aggregate of 34,250
shares of Pulse Biosciences common stock to four new non-executive
employees under the Pulse Biosciences 2017 Inducement Equity
Incentive Plan on September 17, 2018.
The 2017 Inducement Equity Incentive Plan is used exclusively to
grant equity awards to individuals who were not previously an
employee or non-employee director of Pulse Biosciences as an
inducement material to such individual's entering into employment
with Pulse Biosciences in accordance with Nasdaq Marketplace Rule
5635(c)(4).
The options have an exercise price of $14.59 per share, which is
equal to the closing price of Pulse Biosciences common stock on
September 17, 2018. The 34,250 shares underlying the option grants
will vest and become exercisable as to 25% of the shares on the
first anniversary of the recipient’s start date, and will vest and
become exercisable as to the remaining 75% of the shares in 36
equal monthly installments following the first anniversary of the
recipient’s start date, subject to the recipient’s continued
employment with Pulse Biosciences on these vesting dates. The
options are subject to the terms and conditions of the 2017
Inducement Equity Incentive Plan and the award agreements entered
into with each recipient.
About Pulse Biosciences
Pulse Biosciences is a publicly listed clinical stage
electroceutical company pursuing multiple clinical applications of
its proprietary Nano-Pulse Stimulation technology. Nano-Pulse
Stimulation (NPS) is a non-thermal, precise, focal tissue treatment
technology comprised of nanosecond (billionth of a second) range
pulsed electric fields that directly affect the cell membrane and
intracellular structures and initiate cell death in treated cells.
The initiation of cell death by NPS results in a minimal
inflammatory response, which improves healing outcomes and supports
the replacement of treated tissue cells with healthy tissue cells.
NPS’ unique mechanism of action to initiate cell death has the
potential to significantly benefit patients for multiple medical
applications in dermatology, immune-oncology, and in other unique
tissue targets. In cancerous lesions, NPS has been shown in
preclinical models to induce immunogenic cell death (ICD), which
exposes the unique antigens of the treated cells to the immune
system and enrolls immune system cells, such as cytotoxic T-cells
to mount an adaptive immune response. More information is available
at www.pulsebiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180919005716/en/
Investor Relations:Pulse Biosciences, Inc.Brian DowSr.
Vice President and Chief Financial
OfficerIR@pulsebiosciences.comorSolebury TroutGitanjali Jain Ogawa,
646-378-2949gogawa@troutgroup.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Sep 2023 to Sep 2024